We’d love to hear your feedback on this activity. It helps us to continually improve our products.
MYR301 (NCT03852719) is a phase 3 study evaluating the long-term efficacy and safety of bulevirtide in people living with chronic hepatitis delta infection (CHD). In this interview, Prof. Maria Buti (Vall d’Hebron University Hospital, Barcelona, Spain) discusses the results from the exploratory analysis of MYR301, investigating the health-related quality of life (HRQOL) benefits of treatment […]
In some countries, patients considered vulnerable have received 3rd/4th COVID-19 vaccine doses (V3/V4). This study, presented by Stavros Dimitriadis (University of Oxford, Oxford, UK), explores the immune response to V4 in a mixed disease cohort of immunosuppressed patients including liver transplant recipients and patients with autoimmune hepatitis. This study also focused on individuals with absent […]
touchIMMUNOLOGY spoke with Prof. Thomas Berg (University Hospital Leipzig, Leipzig, Germany; Secretary General, EASL) to discuss the burden of hepatitis, the path to diagnosis, and the current treatment options available for hepatitis B, C, and D. Question: What are the unmet needs in diagnosis and treatment of hepatitis? (0:20) Disclosures: Dr Thomas Berg has received grant/research […]
touchIMMUNOLOGY caught up with Dr Emanuel Della Torre (Università Vita-Salute San Raffaele Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, Ospedale San Raffael, Milan, Italy) to discuss the current and future treatment of immunoglobulin G4-related (IgG4) diseases. His presentation entitled ‘Management: current therapy of IgG4-related systemic disease and what is on the horizon‘ was given […]
Get the latest clinical insights from touchIMMUNOLOGY